



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
ATTORNEYS AT LAW
1100 NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934
PHONE: (202) 371-2600 • FACSIMILE: (202) 371-2540 • www.skgf.com

Receipt
RECEIVED
TECH CENTER 1400
DEC 12 2001
NANCY J. LEONHARD
JOSEPH M. MCGRADY III**
DOUGLAS M. WILSON**
ANN E. SUMMERSFIELD**
CYNTHIA M. BOUCHEZ**
HELENE C. CARLSON**
GABY L. LONGSWORTH**
DUSTIN T. JOHNSON**
MATTHEW J. DOWD**
AARON L. SCHWARTZ**
*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX***
DAVID K.S. CORNWELL
ROBERT W. EDMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG

JOHN M. COVERT
LINDA E. ALCORN
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
PATRICK E. GARRETT
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES

EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
VINCENT L. CAPUANO
JOHN A. HARROUN*
ALBERT J. FASULO II*
ELDORA ELLISON FLOYD*

W. RUSSELL SWINDELL
THOMAS C. FIALA
BRIAN J. DEL BUONO*
VIRGIL L. BEASTON*
RYAN J. STAMPER*
REGINALD D. LUCAS*
THEODORE A. WOOD
ELIZABETH J. HAANES
BRUCE E. CHALKER
JOSEPH S. OSTROFF
KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
ANDREA J. KAMAGE**

November 30, 2001

WRITER'S DIRECT NUMBER:
(202) 371-2560
INTERNET ADDRESS:
RESMOND@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

*Attn: Office of Initial Patent
Examination's Customer
Service Center*

Re: U.S. Utility Patent Application
Appl. No. 09/964,666; Filed: September 28, 2001
For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for
the Treatment or Prevention of Alzheimer's Disease**
Inventors: de la Monte *et al.*
Our Ref: 0609.4370003/RWE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Corrected Official Filing Receipt;
2. A photocopy of the instant Official Filing Receipt with corrections noted in red; and
3. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
November 30, 2001
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE/MJC/lam
Enclosures

P:\USERS\MCRONIN\0609.4370003\pto\ofrcorrectionptotrm



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de la Monte *et al.*

Appl. No. 09/964,666

Filed: September 28, 2001

For: **Transgenic Animals and Cell
Lines for Screening Drugs
Effective for the Treatment or
Prevention of Alzheimer's Disease**

Confirmation No. 3650

Art Unit: 1633

Examiner: *To be assigned*

Atty. Docket: 0609.4370003/RW

TECH CENTER 1600/2550

DEC 12 2001

RECEIVED

Request for Corrected Official Filing Receipt

Commissioner for Patents
Washington, D.C. 20231

Attn: Office of Initial Patent
Examination's Customer
Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:

In the Domestic Priority data as claimed by applicant section at line 1, please delete "***"; and at line 4, please delete "(*) Data inconsistent with PTO records." Applicants submit that this data is correct.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: Nov. 30, 2001
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600



O I P E
NOV 30 2001
U.S. PATENT & TRADEMARK OFFICE
TECH CENTER 2200

UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
DEC 1 2001
COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20591
www.uspto.gov

| APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY.DOCKET.NO | DRAWINGS | TOT CLAIMS | IND. CLAIMS |
|--------------------|-------------|--------------|---------------|----------------|----------|------------|-------------|
| 09/964,666 | 09/28/2001 | 1633 | 870 | 0609.4370003 | 13 | 17 | 5 |

CONFIRMATION NO. 3650

26111

STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, DC 20005-3934

FILING RECEIPT



OC000000007040579

Date Mailed: 11/08/2001


Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Suzanne De La Monte, East Greenwich, RI;
Jack R. Wands, Waban, MA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/380,203 04/25/2000
WHICH IS A 371 OF PCT/US98/03685 02/26/1998
WHICH CLAIMS BENEFIT OF 60/038,908 02/26/1997
(* Data inconsistent with PTO records.



Foreign Applications

If Required, Foreign Filing License Granted 11/07/2001

11/13 AJC

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

Title

Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 • FACSIMILE: (202) 371-2540 • www.skgf.com

ROBERT GREENE STERNE JOHN M. COVERT EDWARD W. YEE
EDWARD J. KESSLER LINDA E. ALCORN ALBERT L. FERRO*
JORGE A. GOLDSTEIN ROBERT C. MILLONIG DONALD R. BANOWIT
SAMUEL L. FOX*** MICHAEL V. MESSINGER PETER A. JACKMAN
DAVID K.S. CORNWELL JUDITH U. KIM MOLLY A. MCCALL
ROBERT W. ESMOND TIMOTHY J. SHEA, JR. TERESA U. MEDLER
TRACY-GENE G. DURKIN PATRICK E. GARRETT JEFFREY S. WEAVER
MICHELE A. CIMBALA JEFFREY T. HELVEY* KENDRICK P. PATTERSON
MICHAEL B. RAY HEIDI L. KRAUS DONALD J. FEATHERSTONE
ROBERT E. SOKOHL JEFFREY R. KURIN VINCENT L. CAPUANO
ERIC K. STEFFE PATRICK D. O'BRIEN JOHN A. HARROUN*
MICHAEL O. LEE LAWRENCE B. BUGAISKY ALBERT J. FASULO II*
STEVEN R. LUDWIG CRYSTAL D. SAYLES ELDORA ELLISON FLOYD*

W. RUSSELL SWINDELL THOMAS C. FIALA
BRIAN J. DEL BUONO* VIRGIL L. BEASTON*
REGINALD D. LUCAS* RYAN J. STAMPER*
THEODORE A. WOOD THEODORE A. WOOD
ELIZABETH J. HAANES BRUCE E. CHALKER
JOSEPH S. OSTROFF KAREN R. MARKOWICZ**
SUZANNE E. ZISKA** ANDREA J. KAMAGE**

NANCY J. LEITH** JOSEPH M. CONRAD, III
DOUGLAS M. WILSON** ANN E. SUMMERFIELD**
CYNTHIA M. BOUCHEZ** HELENE C. CARLSON**
GABY L. LONGSWORTH** DUSTIN T. JOHNSON**
MATTHEW J. DOWD** AARON L. SCHWARTZ**
*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

November 30, 2001

WRITER'S DIRECT NUMBER:
(202) 371-2560
INTERNET ADDRESS:
RESMOND@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Group Art Unit 1633

Re: U.S. Utility Patent Application
Appl. No. 09/964,666; Filed: September 28, 2001
For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for
the Treatment or Prevention of Alzheimer's Disease**
Inventors: de la Monte *et al.*
Our Ref: 0609.4370003/RWE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Substitute Application Data Sheet; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. A duplicate copy of this letter is enclosed.


RECEIVED
DEC 03 2001
TECH CENTER 1600/2000

Commissioner for Patents
November 30, 2001
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE/MJC/lam
Enclosures

P:\USERS\MCRONIN\0609.4370003\pto\applicationdatasheetptotrn